Abstracts

TUBERCULOSIS IN HIV-ASSOCIATED CRYPTOCOCCAL MENINGITIS AND ITS IMPACT ON MORTALITY

Tuberculosis (TB) and cryptococcal meningitis are leading causes of morbidity and mortality in advanced HIV. Data on TB co-infection amongst people with cryptococcosis is scarce. We described the occurrence of TB in Ugandan adults with cryptococcal meningitis and determined the impact of co-infection on survival. We performed a retrospective analysis of patients diagnosed with cryptococcal…

EVALUATING THE IMMY SEMI-QUANTITATIVE CrAg LFA IN HIV-POSITIVE PATIENTS IN BOTSWANA

Cryptococcal antigen (CrAg) titers are an important prognostic indicator in HIV-positive patients with cryptococcal infection and could potentially be used to stratify treatment. Current titration methods are expensive and labor intensive. A novel semi-quantitative (SQ) CrAg test has been developed that can provide an indication of CrAg titer using a simple dipstick lateral flow assay (LFA).…

HIGH RATES OF MENINGITIS OR MORTALITY AMONG CrAg+ PLHIV WITH CD4 100-200 CELLS/MM³

Cryptococcal antigen (CrAg) screening with fluconazole prophylaxis has been shown to prevent cryptococcal meningitis and mortality for people living with HIV (PLHIV) with CD4 <100 cells/mm3. While cryptococcal meningitis occurs in individuals with CD4 100-200 cells/mm3, there is limited evidence that CrAg screening predicts cryptococcal meningitis or mortality among this group with moderate immunosuppression. Current…

CSF CYTOKINES AND CHEMOKINES ASSOCIATED WITH MORTALITY IN CRYPTOCOCCAL MENINGITIS

Cryptococcal meningitis causes substantial mortality globally. Our understanding of the role of the host immune system in patient outcomes is limited.  We investigated the cytokine and chemokine environment at the site of infection, the CNS, to better understand the impact of immune cell activation and tissue inflammation on mortality. We prospectively enrolled Ugandans presenting with first episode…

EARLY FUNGICIDAL ACTIVITY AS SURROGATE ENDPOINT FOR CRYPTOCOCCAL MENINGITIS SURVIVAL

In cryptococcal meningitis phase 2 clinical trials, early fungicidal activity (EFA) of Cryptococcus yeast clearance from cerebrospinal fluid (CSF) is used as a surrogate endpoint. The US FDA allows for surrogate endpoints for accelerated regulatory approval, but there are no accepted surrogate endpoints for this neglected disease. For tuberculosis, the FDA recognizes an official surrogate endpoint…

N-ACETYLCYSTEINE FOR ANTI-TB DRUG-INDUCED LIVER INJURY: A RANDOMISED CONTROLLED TRIAL

First-line anti-tuberculosis (TB) therapy can cause liver injury. N-Acetylcysteine (NAC) is widely used in patients with paracetamol toxicity and there is limited evidence of benefit in liver injury due to other causes. We conducted a randomised, double-blind, placebo-controlled trial to assess whether intravenous NAC improves liver recovery in adult patients admitted to hospital with first-line…